Estonian Pharmapark joins forces with Holland veterinary medicine leading brands Interchemie and Kepro

Tallinn, Estonia – Estonian veterinary pharmaceutical company Pharmapark OÜ has entered into a new strategic partnership with Dutch veterinary medicine brands Interchemie and Kepro. Together, the parties announced the creation of a new Dutch–Estonian joint venture under the name Interchemie.

As part of the agreement, Veiko Saluste, will continue in his role as Managing Director of Pharmapark.

“There is a strong rationale for Interchemie to work with Pharmapark. We bring a state-of-the-art GMP-certified production facility into this new venture, creating opportunities for growth with quality and capacity guaranteed,” said Veiko Saluste.

The new company will be led by Bernard Verburg, appointed as Chief Executive Officer.

“We strongly believe that this new venture will be a powerful one. By combining our strengths in marketing, sales, and manufacturing of world-class veterinary medicines, we can offer customers more choice, excellent quality and service, while securing production capacity and compliance. In doing so, we aim to achieve a world-leading position in generic veterinary pharmacy,” said Bernard Verburg.

During the formation of the joint venture, Interchemie B.V. became the sole owner of Pharmapark OÜ and Pharmapark Production OÜ.

Transition of production and workforce

The production and supply chain operations of Interchemie veterinary medicines in Estonia will be gradually transferred from Viimsi and Maardu to the Pharmapark factory in Tallinn. Employees from these sites will be invited to join the Pharmapark team, ensuring continuity and leveraging existing expertise.

This announcement builds on the previous agreement signed between Pharmapark and Interchemie. Under that agreement, Pharmapark would only supply Interchemie with selected products, offering contract manufacturing capacity. The collaboration has now evolved into a joint venture with an integration of all activities.

Pharmapark: One of Europe’s largest veterinary medicine factories

In 2024, Pharmapark inaugurated one of Europe’s largest and most modern veterinary medicine factories in Tallinn following a €50 million investment. The facility primarily serves export markets, underscoring Estonia’s growing role in the global pharmaceutical industry.In spring 2025, the Estonian State Agency of Medicines granted Pharmapark Production OÜ’s chemical laboratory a Good Manufacturing Practice (GMP) certificate, confirming compliance with EU regulatory requirements and international quality standards. This certification enables full access to global export markets and strengthens Pharmapark’s competitive position.Certified laboratories provide Pharmapark with a solid foundation for the continued development of its quality system, including the production of sterile and aseptic medicines, ensuring adherence to the strictest regulatory requirements.